Catch Up on the Latest MBC Research!
If you or a loved one has MBC, take a look at the summary of cutting-edge MBC research disclosed at the San Antonio Breast Cancer Symposium (SABCS) in Dec. 2021! There's encouraging news for individuals with each subtype of MBC, and all information has been incorporated into my book, "The Insider's Guide to Metastatic Breast Cancer," which is also available as a complimentary .pdf.
Here's a sample from the document:
For Patients with TNBC MBC: Datopotamab Deruxtecan (Dato-DXd) is an Antibody Drug Conjugate (ADC) that was studied in the TROPION-PanTumor01 Phase 1 Trial. The 44 patients enrolled in the study had been treated with a median of three prior therapies in the metastatic setting, including taxanes, platinum-based chemotherapy, immunotherapy, other ADCs, and PARP inhibitors. The overall Objective Response Rate (ORR) was 34%, and in the subgroup of 27 patients who had not previously been treated with a TROP-2-directed drug (such as Trodelvy) the ORR was 52%.
Want to see more? Visit: https://www.insidersguidembc.com/sabcs